EV/FCF Ratio: 46.79x
Is the EV/FCF ratio high or low?
The EV/FCF ratio of 46.79x is 32% below its 5-year average of 68.82x, near the low end of its 5-year range (32.26x–235.73x).
As of Monday, June 29, 2026. 16.01% below its 12-month average of 55.71x.
EW EV/FCF Ratio Chart
EW Average EV/FCF Ratio Chart
EW Current vs Average EV/FCF Ratio Chart
EW EV/FCF Ratio Metrics
EV/FCF RATIO
46.79x
EV/FCF RATIO AVG TTM
55.71x
EV/FCF RATIO AVG 3Y
64.27x
EV/FCF RATIO AVG 5Y
59.47x
EV/FCF RATIO AVG 10Y
56.51x
EV/FCF RATIO AVG 15Y
48.91x
EV/FCF RATIO AVG 20Y
45.56x
CURRENT VS TTM AVG
-16.01%
CURRENT VS 3Y AVG
-27.20%
CURRENT VS 5Y AVG
-21.32%
CURRENT VS 10Y AVG
-17.19%
CURRENT VS 15Y AVG
-4.34%
CURRENT VS 20Y AVG
+2.69%
EW Competitors' EV/FCF Ratio
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation (EW) | $52.61B | 46.79x | 55.71x | 64.27x | 59.47x |
| Cencora, Inc. (COR)vs › | $55.67B | 42.39x | 35.36x | 22.97x | 19.78x |
| Cardinal Health, Inc. (CAH)vs › | $55.72B | 13.92x | 14.79x | 13.55x | 13.89x |
| Becton, Dickinson and Company (BDX)vs › | $56.49B | 19.17x | 23.20x | 27.39x | 30.76x |
| Humana Inc. (HUM)vs › | $46.08B | 43.52x | 34.68x | 22.22x | 31.87x |
| IDEXX Laboratories, Inc. (IDXX)vs › | $43.50B | 42.05x | 55.92x | 56.31x | 65.67x |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $65.20B | 16.34x | 18.35x | 23.50x | 21.48x |
| Boston Scientific Corporation (BSX)vs › | $65.74B | 21.97x | 40.07x | 58.15x | 66.03x |
| Agilent Technologies, Inc. (A)vs › | $38.41B | 31.99x | 34.63x | 30.03x | 33.41x |
| Medline Inc. (MDLN)vs › | $32.87B | 27.85x | 27.66x | 27.66x | 27.66x |
Cash Flow Valuation Comparison
EV/FCF
46.8x
P/FCF
48.4x
FCF Yield
2.07%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
- EV/FCF accounts for debt and cash through enterprise value
- P/FCF only considers equity value
- EV/FCF can be compared across companies with different debt levels
- Both measure how the market values cash generation
EV/FCF Ratio Formula & Definition
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
EV/FCF Ratio FAQ
- What is the EV/FCF ratio for Edwards Lifesciences Corporation (EW)?
- The EV/FCF ratio for EW stock is 46.79x.
- Is Edwards Lifesciences Corporation's EV/FCF ratio high or low?
- The EV/FCF ratio of 46.79x is 32% below its 5-year average of 68.82x, near the low end of its 5-year range (32.26x–235.73x).
- What is the TTM average EV/FCF ratio for Edwards Lifesciences Corporation (EW)?
- The TTM average EV/FCF ratio for EW stock is 55.71x.
- What is the 3Y average EV/FCF ratio for Edwards Lifesciences Corporation (EW)?
- The 3Y average EV/FCF ratio for EW stock is 64.27x.
- What is the 5Y average EV/FCF ratio for Edwards Lifesciences Corporation (EW)?
- The 5Y average EV/FCF ratio for EW stock is 59.47x.
- What is the 10Y average EV/FCF ratio for Edwards Lifesciences Corporation (EW)?
- The 10Y average EV/FCF ratio for EW stock is 56.51x.
- What is the 15Y average EV/FCF ratio for Edwards Lifesciences Corporation (EW)?
- The 15Y average EV/FCF ratio for EW stock is 48.91x.
- What is the 20Y average EV/FCF ratio for Edwards Lifesciences Corporation (EW)?
- The 20Y average EV/FCF ratio for EW stock is 45.56x.
EW EV/FCF Ratio History
| DATE | EV/FCF RATIO |
|---|---|
| 2026-06-26 | 46.79x |
| 2026-06-25 | 46.22x |
| 2026-06-24 | 46.19x |
| 2026-06-23 | 44.74x |
| 2026-06-22 | 44.17x |
| 2026-06-18 | 44.96x |
| 2026-06-17 | 44.60x |
| 2026-06-16 | 45.61x |
| 2026-06-15 | 44.39x |
| 2026-06-12 | 43.76x |
| 2026-06-11 | 44.11x |
| 2026-06-10 | 44.23x |
| 2026-06-09 | 45.06x |
| 2026-06-08 | 44.16x |
| 2026-06-05 | 44.22x |
| 2026-06-04 | 45.01x |
| 2026-06-03 | 44.24x |
| 2026-06-02 | 45.12x |
| 2026-06-01 | 45.39x |
| 2026-05-29 | 44.49x |
| 2026-05-28 | 44.22x |
| 2026-05-27 | 44.51x |
| 2026-05-26 | 45.06x |
| 2026-05-22 | 44.12x |
| 2026-05-21 | 42.74x |
| 2026-05-20 | 42.62x |
| 2026-05-19 | 42.19x |
| 2026-05-18 | 42.31x |
| 2026-05-15 | 41.77x |
| 2026-05-14 | 41.75x |
| 2026-05-13 | 41.78x |
| 2026-05-12 | 40.90x |
| 2026-05-11 | 39.53x |
| 2026-05-08 | 41.02x |
| 2026-05-07 | 42.51x |
| 2026-05-06 | 42.74x |
| 2026-05-05 | 34.46x |
| 2026-05-04 | 34.64x |
| 2026-05-01 | 34.93x |
| 2026-04-30 | 34.72x |
| 2026-04-29 | 33.72x |
| 2026-04-28 | 34.19x |
| 2026-04-27 | 34.70x |
| 2026-04-24 | 35.00x |
| 2026-04-23 | 33.07x |
| 2026-04-22 | 33.86x |
| 2026-04-21 | 33.07x |
| 2026-04-20 | 33.82x |
| 2026-04-17 | 33.62x |
| 2026-04-16 | 32.78x |
| 2026-04-15 | 32.41x |
| 2026-04-14 | 32.41x |
| 2026-04-13 | 32.37x |
| 2026-04-10 | 32.26x |
| 2026-04-09 | 32.82x |
| 2026-04-08 | 33.94x |
| 2026-04-07 | 33.56x |
| 2026-04-06 | 33.71x |
| 2026-04-02 | 33.65x |
| 2026-04-01 | 33.74x |
| 2026-03-31 | 33.23x |
| 2026-03-30 | 32.97x |
| 2026-03-27 | 32.90x |
| 2026-03-26 | 34.11x |
| 2026-03-25 | 34.36x |
| 2026-03-24 | 33.93x |
| 2026-03-23 | 34.07x |
| 2026-03-20 | 34.28x |
| 2026-03-19 | 34.26x |
| 2026-03-18 | 34.33x |
| 2026-03-17 | 35.05x |
| 2026-03-16 | 34.74x |
| 2026-03-13 | 33.98x |
| 2026-03-12 | 35.21x |
| 2026-03-11 | 35.41x |
| 2026-03-10 | 35.71x |
| 2026-03-09 | 35.05x |
| 2026-03-06 | 33.91x |
| 2026-03-05 | 34.89x |
| 2026-03-04 | 35.47x |
| 2026-03-03 | 35.49x |
| 2026-03-02 | 36.32x |
| 2026-02-27 | 36.01x |
| 2026-02-26 | 35.76x |
| 2026-02-25 | 34.67x |
| 2026-02-24 | 57.54x |
| 2026-02-23 | 57.57x |
| 2026-02-20 | 55.64x |
| 2026-02-19 | 55.01x |
| 2026-02-18 | 55.05x |
| 2026-02-17 | 54.67x |
| 2026-02-13 | 52.79x |
| 2026-02-12 | 53.20x |
| 2026-02-11 | 55.31x |
| 2026-02-10 | 53.65x |
| 2026-02-09 | 53.46x |
| 2026-02-06 | 54.86x |
| 2026-02-05 | 54.41x |
| 2026-02-04 | 55.63x |
| 2026-02-03 | 57.32x |
| 2026-02-02 | 57.73x |
| 2026-01-30 | 56.79x |
| 2026-01-29 | 56.88x |
| 2026-01-28 | 57.15x |
| 2026-01-27 | 58.42x |
| 2026-01-26 | 58.91x |
| 2026-01-23 | 58.46x |
| 2026-01-22 | 59.03x |
| 2026-01-21 | 59.54x |
| 2026-01-20 | 58.32x |
| 2026-01-16 | 58.96x |
| 2026-01-15 | 59.07x |
| 2026-01-14 | 58.05x |
| 2026-01-13 | 58.59x |
| 2026-01-12 | 57.99x |
| 2026-01-09 | 59.53x |
| 2026-01-08 | 59.13x |
| 2026-01-07 | 59.31x |
| 2026-01-06 | 60.06x |
| 2026-01-05 | 58.83x |
| 2026-01-02 | 59.68x |
| 2025-12-31 | 59.62x |
| 2025-12-30 | 60.31x |
| 2025-12-29 | 60.85x |
| 2025-12-26 | 60.78x |
| 2025-12-24 | 60.38x |
| 2025-12-23 | 60.33x |
| 2025-12-22 | 60.55x |
| 2025-12-19 | 59.92x |
| 2025-12-18 | 59.29x |
| 2025-12-17 | 59.32x |
| 2025-12-16 | 59.67x |
| 2025-12-15 | 58.26x |
| 2025-12-12 | 58.04x |
| 2025-12-11 | 58.88x |
| 2025-12-10 | 58.65x |
| 2025-12-09 | 58.18x |
| 2025-12-08 | 58.94x |
| 2025-12-05 | 60.30x |
| 2025-12-04 | 60.01x |
| 2025-12-03 | 58.69x |
| 2025-12-02 | 59.23x |
| 2025-12-01 | 59.63x |
| 2025-11-28 | 60.65x |
| 2025-11-26 | 60.71x |
| 2025-11-25 | 60.76x |
| 2025-11-24 | 59.23x |
| 2025-11-21 | 59.53x |
| 2025-11-20 | 58.77x |
| 2025-11-19 | 60.18x |
| 2025-11-18 | 58.74x |
| 2025-11-17 | 59.25x |
| 2025-11-14 | 60.38x |
| 2025-11-13 | 60.25x |
| 2025-11-12 | 59.86x |
| 2025-11-11 | 59.55x |
| 2025-11-10 | 58.77x |
| 2025-11-07 | 58.26x |
| 2025-11-06 | 57.57x |
| 2025-11-05 | 57.86x |
| 2025-11-04 | 77.15x |
| 2025-11-03 | 76.11x |
| 2025-10-31 | 75.51x |
| 2025-10-30 | 76.51x |
| 2025-10-29 | 75.74x |
| 2025-10-28 | 75.26x |
| 2025-10-27 | 73.93x |
| 2025-10-24 | 69.37x |
| 2025-10-23 | 69.78x |
| 2025-10-22 | 70.08x |
| 2025-10-21 | 69.29x |
| 2025-10-20 | 68.58x |
| 2025-10-17 | 67.96x |
| 2025-10-16 | 66.03x |
| 2025-10-15 | 66.30x |
| 2025-10-14 | 66.72x |
| 2025-10-13 | 66.32x |
| 2025-10-10 | 67.28x |
| 2025-10-09 | 68.49x |
| 2025-10-08 | 69.02x |
| 2025-10-07 | 69.97x |
| 2025-10-06 | 69.81x |
| 2025-10-03 | 70.31x |
| 2025-10-02 | 69.90x |
| 2025-10-01 | 69.57x |
| 2025-09-30 | 70.98x |
| 2025-09-29 | 70.42x |
| 2025-09-26 | 69.51x |
| 2025-09-25 | 68.57x |
| 2025-09-24 | 67.98x |
| 2025-09-23 | 67.89x |
| 2025-09-22 | 67.10x |
| 2025-09-19 | 67.73x |
| 2025-09-18 | 67.87x |
| 2025-09-17 | 68.50x |
| 2025-09-16 | 68.39x |
| 2025-09-15 | 69.32x |
| 2025-09-12 | 70.79x |
| 2025-09-11 | 71.22x |
| 2025-09-10 | 71.48x |
| 2025-09-09 | 72.95x |
| 2025-09-08 | 73.34x |
| 2025-09-05 | 74.05x |
| 2025-09-04 | 74.07x |
| 2025-09-03 | 74.32x |
| 2025-09-02 | 74.85x |
| 2025-08-29 | 74.44x |
| 2025-08-28 | 74.33x |
| 2025-08-27 | 74.01x |
| 2025-08-26 | 74.37x |
| 2025-08-25 | 73.97x |
| 2025-08-22 | 74.91x |
| 2025-08-21 | 74.26x |
| 2025-08-20 | 74.48x |
| 2025-08-19 | 72.11x |
| 2025-08-18 | 71.50x |
| 2025-08-15 | 71.46x |
| 2025-08-14 | 71.38x |
| 2025-08-13 | 70.90x |
| 2025-08-12 | 70.17x |
| 2025-08-11 | 71.36x |
| 2025-08-08 | 71.54x |
| 2025-08-07 | 71.14x |
| 2025-08-06 | 71.80x |
| 2025-08-05 | 67.58x |
| 2025-08-04 | 68.34x |
| 2025-08-01 | 67.66x |
| 2025-07-31 | 67.64x |
| 2025-07-30 | 69.31x |
| 2025-07-29 | 68.69x |
| 2025-07-28 | 66.90x |
| 2025-07-25 | 68.26x |
| 2025-07-24 | 64.48x |
| 2025-07-23 | 65.48x |
| 2025-07-22 | 64.93x |
| 2025-07-21 | 65.17x |
| 2025-07-18 | 65.10x |
| 2025-07-17 | 64.83x |
| 2025-07-16 | 64.79x |
| 2025-07-15 | 65.39x |
| 2025-07-14 | 66.72x |
| 2025-07-11 | 66.51x |
| 2025-07-10 | 67.18x |
| 2025-07-09 | 65.73x |
| 2025-07-08 | 65.01x |
| 2025-07-07 | 65.28x |
| 2025-07-03 | 65.37x |
| 2025-07-02 | 65.58x |
| 2025-07-01 | 65.73x |
| 2025-06-30 | 66.65x |
| 2025-06-27 | 66.65x |
| 2025-06-26 | 65.70x |
| 2025-06-25 | 65.54x |
| 2025-06-24 | 64.53x |
| 2025-06-23 | 64.05x |
| 2025-06-20 | 62.71x |
| 2025-06-18 | 62.85x |
| 2025-06-17 | 62.21x |
| 2025-06-16 | 63.60x |
| 2025-06-13 | 63.90x |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Bernard J. Zovighian